AstraZeneca’s Mystic OS analysis paints tremelimumab as a dud in NSCLC

AstraZeneca
AstraZeneca's Cambridge, U.K. R&D center. (AstraZeneca)

Overall survival data from AstraZeneca’s phase 3 Mystic trial have cast more doubts on the prospects of anti-CTLA4 antibody tremelimumab. The readout suggests that, if anything, adding tremelimumab to PD-L1 drug Imfinzi results in worse outcomes in metastatic non-small cell lung cancer (NSCLC).

In keeping with earlier Mystic readouts, the OS data features more black clouds than silver linings. The latest analysis shows how Imfinzi, with or without tremelimumab, performed against standard of care chemotherapy in previously untreated patients with metastatic NSCLC. At least 25% of cancer cells in the analyzed patient population expressed PD-L1.

Neither Imfinzi nor Imfinzi plus tremelimumab delivered statistically better OS than platinum-based chemotherapy, the standard of care comparator. To compound matters, the OS data raise questions about whether tremelimumab is hindering, not helping.

Sponsored by Biotech Primer

September 2-3, 2020 Live, Online Course: Biopharma Revenue Forecasting that Drives Decision Making and Investments

Become fluent in the core elements of revenue forecasting including epidemiology, competitive assessments, market share assignment and pricing. Let Biotech Primer's dynamic industry experts teach you how to assess the value of new therapies.

AstraZeneca pointed to a hazard ratio of 0.76 in the Imfinzi monotherapy arm as a cause for a degree of optimism. That suggests Imfinzi may be better than standard of care. But the difference was too small to hit statistical significance—the p value was 0.036—and the confidence interval is too broad to rule out that Imfinzi is no better than chemotherapy.

That was the positive part of the analysis. The picture darkens once tremelimumab is involved. When the CTLA-4 drug was added to Imfinzi, the HR came in at 0.85, suggesting patients may have lived longer if they received the PD-L1 inhibitor as a monotherapy.

AstraZeneca saw Mystic as a way to leapfrog its rivals and establish Imfinzi plus tremelimumab as a first-line treatment in NSCLC. The delivery of progression-free survival data last year put a big dent in that plan. And the inability of either of AstraZeneca’s regimens to extend overall survival has dealt it another big blow.

Research is continuing, though. AstraZeneca thinks the OS data justify further analysis in exploratory subgroups, although the available evidence leaves little scope for optimism about tremelimumab.

Elsewhere, AstraZeneca is continuing to test Imfinzi in combination with tremelimumab in two other phase 3 first-line NSCLC trials, dubbed Neptune and Poseidon.

Suggested Articles

According to a large clinical study, multifocal contact lenses were able to slow down and control the worsening of nearsightedness in children.

RapidAI has secured an FDA clearance for its artificial intelligence algorithms that quickly parse brain CT scans and spot suspected strokes.

The kits can connect 20 standard hospital beds to a central patient monitoring station and be up and running in an average of five hours.